Pelat and coworkers 1 demonstrated that rosuvastatin decreases caveolin-1 expression in the cardiovasculature of dyslipidemic mice. By decreasing the expression of caveolin-1, an inhibitor of endothelial NO synthase, rosuvastatin treatment promotes endothelial NO synthase function and concomitantly stabilizes heart rate and blood pressure variabilities. Thus, rosuvastatin exerts beneficial effects on vascular function beyond those attributed to its lipid-lowering capacity. The authors presume that caveolin-1 downregulation occurs at the endothelial cell level, although they also envisioned additional effects on other vascular cells involved in atherogenesis.
Response
Plenz et al emphasize the potential cell specificity for the action of statins on caveolin-1 expression, as well as the difference among statins. Although one may envisage several hypotheses for the differential regulation in vitro, perhaps a more important issue is its impact on atherogenesis and vascular function in vivo.
The caveolin-1 gene contains several sterol regulatory elements (SREs) in its promoter, enabling its transcriptional regulation by cholesterol-responsive SRE binding proteins (SREBPs) among other factors. In human fibroblasts exposed to LDL particles (resulting in enrichment in intracellular free cholesterol), caveolin-1 mRNA increased. 1 Similarly, we showed that exposure of endothelial cells to LDL cholesterol in vitro and in vivo resulted in an increase in caveolin-1 protein. 2, 3 This was paralleled with increased interaction between caveolin-1 and endothelial NO synthase (eNOS), resulting in functional inhibition of eNOS activity and NO production. Statins, on the other hand, decreased caveolin-1 protein abundance in endothelial cells in proportion to their inhibition of intracellular cholesterol synthesis and resultant decrease in free cholesterol concentration. 4 Importantly, this resulted in improved eNOS function, both in vitro 4 and in vivo. 3 The fact that similar effects on caveolin-1 were obtained with at least two different statins (atorvastatin and rosuvastatin) suggests a common mechanism related to Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibition (this was also mevalonate-reversible in our hands). In other cell types, Plenz et al refer to the absence of effect of other statins in vitro, which is perhaps attributable to differences in physicochemical properties (eg, hydrophilicity), although this does not preclude well-established clinical benefits with the same drug(s) in clinical trials.
Improved eNOS activity with statins in the endothelium likely contributes to the improvements in NO-dependent cardiovascular function, such as blood pressure and heart rate variability. 3 Provided it is confirmed at the protein level and in vivo, the differential regulation of caveolin-1 in other vascular cell types, as proposed by Plenz et al, may contribute as well. For example, increases in caveolin-1 may promote cholesterol export from these cells. However, important features still need verification. In vitro, the effect of LDL exposure on caveolae density (and cholesterol export) markedly differs according to the phenotype (ie, synthetic versus contractile) of vascular smooth muscle cells. 5 Similar phenotypic differences in response to statins may be anticipated. The fate of caveolin-3, an important isoform in muscle cells, also remains undetermined. In peritoneal macrophages, increases in caveolin-1 are paralleled with increased apoptosis, although the two phenomena may not be causally related. If simvastatin produces similar events in macrophages, as proposed by Plenz et al, and if verified in vivo, a resultant decreased inflammatory infiltrate may hypothetically contribute to the benefits of statins on the vessel wall. 
